SCHEMBL6943859

SCHEMBL6943859

NC1CCN(Cc2cccc(F)c2F)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.49
GAA P10253 1/20 0.48
ALDH1A1 P00352 1/20 0.47
CYP2A13 Q16696 1/20 0.45
SIGMAR1 Q99720 1/20 0.42
JAK2 O60674 1/20 0.42
JAK3 P52333 1/20 0.42
CXCR4 P61073 1/20 0.42
AR P10275 1/20 0.42
ACHE P22303 2/20 0.41
OPRK1 P41145 1/20 0.41
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
CHRM4 P08173 1/20 0.41
POLB P06746 1/20 0.40
KMT2A Q03164 1/20 0.40
RORC P51449 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858039 0.87 ALDH1A1 (0.64) ATMALDH1A1CYP2A13SIGMAR1CXCR4
SCHEMBL13376812 0.84 OPRM1 (0.46) ATMSIGMAR1MAOAMAOB
SCHEMBL6941742 0.81 ALDH1A1 (0.54) ATMGAAALDH1A1CYP2A13SIGMAR1
SCHEMBL6803849 0.81 ALDH1A1 (0.70) ATMGAAALDH1A1CYP2A13AR
SCHEMBL29585689 0.81 ALDH1A1 (0.48) ATMGAAALDH1A1SIGMAR1CHRM4
SCHEMBL13202916 0.80 CXCR3 (0.48) ATMGAAALDH1A1SIGMAR1JAK2
SCHEMBL30341108 0.80 ALDH1A1 (0.73) ATMGAAALDH1A1CYP2A13AR
SCHEMBL14708215 0.77 JAK2 (0.52) ATMGAAALDH1A1CYP2A13JAK2
SCHEMBL6384809 0.77 ALDH1A1 (0.50) GAAALDH1A1CYP2A13ARPOLB
SCHEMBL2925434 0.77 LMNA (0.54) GAAALDH1A1CYP2A13SIGMAR1CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11236122-B2 Triterpene amine derivatives DFH THERAPEUTICS (US) 2022-02-01 US disclosed
US-20210253627-A1 TRITERPENE AMINE DERIVATIVES THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2021-08-19 US disclosed
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 US disclosed
EP-1056744-A1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 EP disclosed
WO-1999043675-A1 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253627-A1 TRITERPENE AMINE DERIVATIVES BET1, PGGT1B, NFATC1 ATM 3591/4885GAA 1978/4885ALDH1A1 3332/4885
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 ATM 2098/4885GAA 3891/4885ALDH1A1 2147/4885
US-11236122-B2 Triterpene amine derivatives BET1, PGGT1B, NFATC1 ATM 3591/4885GAA 1978/4885ALDH1A1 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.